Northwestern University Lead Academic Participating Site, GY4 Supplemental Request

摘要/摘要： 西北大学罗伯特·H·卢里综合癌症中心(LCC)具有悠久的NCTN历史 自1973年以来以经社理事会成员身份参加。目前，LCC基础设施支持参与 通过ECOG-ACRIN、SWOG、Alliance、NRG和COG进行的临床试验和辅助研究。LCC有一个 建立了积累和参与NCTN试验的历史，包括在 2015年、2016年和2017年。 2019年，西北大学被指定为领先的学术表演场地(LAPS)，在这一新的 角色继续显著增加患者参加NCTN试验，这两年都超过了计划的应计目标 一个圈内的机构。 通过继续展示重大科学成就和新举措，招募 优秀的高级教员和高效的初级教员，全面和集成的基础设施 监督癌症相关临床试验，LCC将继续扩大对NCTN试验的参与，提供 科学地领导关键的网络活动，增加机构间的合作和获得独特的 科学资源，以促进癌症干预。

Summary/Abstract: The Robert H. Lurie Comprehensive Cancer Center of Northwestern University (LCC) has a long history of NCTN participation with ECOG membership since 1973. Currently, the LCC infrastructure supports participation in clinical trials and ancillary studies through the ECOG-ACRIN, SWOG, Alliance, NRG, and COG. LCC has an established history of accruing to and participating in NCTN trials including selection as a high performing site in 2015, 2016 and 2017. In 2019, Northwestern University was designated as a Lead Academic Performing site (LAPS) and in this new role continues to significantly accrue patients to NCTN trials, exceeding planned accrual goals in both years as a LAPS institution. Through continued demonstration of significant scientific accomplishments and new initiatives, recruitment of accomplished senior faculty and productive junior faculty, comprehensive and integrated infrastructure for oversight of cancer-related clinical trials, LCC will continue to expand participation in NCTN trials, provide scientific leadership of key network activities, and increase inter-institutional collaborations and access to unique scientific resources, to advance cancer interventions.